Drug intelligence / Profile preview

AH006

Development stage: Preclinical
Lead developer: Apricity Health

Overview

AH006 is a preclinical-stage precision cancer therapy being developed by Apricity Health. It is part of a pipeline of candidates (AH001 through AH009) discovered using the company's proprietary platform, which leverages real-world data and human insights to identify targets driving resistance to current standards of care. The program aims to treat cancer patients who are non-responsive to existing therapies through a biomarker-selected approach. As of early 2024, AH006 is in the preclinical phase of development, specifically targeting mechanisms that allow tumors to evade the existing standard of care.

Beyond the preview

Go deeper on AH006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AH006.

Explore the full profile